MCID: CLR108
MIFTS: 64

Colorectal Adenoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenoma

MalaCards integrated aliases for Colorectal Adenoma:

Name: Colorectal Adenoma 12 29 6 15 17
Adenoma of Large Intestine 71
Colorectal Adenomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050860
UMLS 71 C1302401

Summaries for Colorectal Adenoma

Disease Ontology : 12 An intestinal benign neoplasm that has material basis in epithelial tissue of glandular origin and is located in colon and located in rectum.

MalaCards based summary : Colorectal Adenoma, also known as adenoma of large intestine, is related to polyposis syndrome, hereditary mixed, 1 and mismatch repair cancer syndrome. An important gene associated with Colorectal Adenoma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are ERK Signaling and fMLP Pathway. The drugs Anesthetics and Calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include colon, rectum and testes, and related phenotypes are Decreased Salmonella enterica Typhimurium membrane closure and Reduced mammosphere formation

Wikipedia : 74 The colorectal adenoma is a benign glandular tumor of the colon and the rectum. It is a precursor lesion... more...

Related Diseases for Colorectal Adenoma

Diseases related to Colorectal Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
# Related Disease Score Top Affiliating Genes
1 polyposis syndrome, hereditary mixed, 1 33.7 PTGS2 MUTYH MLH1 GREM1 APC
2 mismatch repair cancer syndrome 33.5 MSH2 MLH1 CTNNB1 APC
3 myh-associated polyposis 33.1 MUTYH MSH2 KRAS HRAS APC
4 adenoma 31.7 TP53 PTGS2 ODC1 MUTYH MSH2 MLH1
5 villous adenoma 31.5 MLH1 KRAS HRAS APC
6 attenuated familial adenomatous polyposis 31.3 MUTYH MSH2 APC
7 colon adenoma 31.1 VDR MIR15A KRAS APC
8 adenocarcinoma 31.0 TP53 PTGS2 MYC MSH2 MLH1 KRAS
9 in situ carcinoma 30.7 TP53 MYC MIR17 HRAS CDH1
10 colitis 30.7 PTGS2 MSH2 MLH1 CTNNB1
11 atrophic gastritis 30.7 TP53 PTGS2 ODC1
12 hyperplastic polyposis syndrome 30.7 TP53 MUTYH KRAS APC
13 gastritis 30.7 TP53 PTGS2 ODC1 CDH1
14 mucinous adenocarcinoma 30.6 TP53 MLH1 KRAS
15 microinvasive gastric cancer 30.6 TP53 MLH1 CDH1
16 peutz-jeghers syndrome 30.5 TP53 CTNNB1 APC
17 colorectal adenocarcinoma 30.5 TP53 PTGS2 MYC MSH2 MLH1 KRAS
18 peptic ulcer disease 30.4 TP53 PTGS2 HRAS
19 familial adenomatous polyposis 30.4 TP53 PTGS2 ODC1 MYC MUTYH MSH2
20 familial colorectal cancer 30.3 TP53 MUTYH MSH2 MLH1 GREM1 CDH1
21 ascending colon cancer 30.3 MSH2 MLH1 KRAS HRAS
22 juvenile polyposis syndrome 30.3 PTGS2 MUTYH MSH2 MLH1 GREM1 APC
23 appendix adenocarcinoma 30.2 KRAS HRAS
24 meningioma, familial 30.1 TP53 MYC MGMT IGF1 CDH1
25 large intestine cancer 30.1 MIR21 MIR17 MIR15A KRAS HRAS APC
26 tubular adenocarcinoma 30.1 MIR21 CTNNB1 CDH1
27 familial adenomatous polyposis 1 30.1 CTNNB1 APC
28 basal cell carcinoma 30.0 VDR TP53 PTGS2 MSH2 MLH1 CTNNB1
29 lynch syndrome 29.9 TP53 MUTYH MTHFR MSH2 MLH1 MIR17
30 lymphoma 29.9 TP53 MYC MSH2 MGMT IGF1 CDH1
31 hepatoblastoma 29.9 TP53 MYC MIR21 CTNNB1 APC
32 osteoporosis 29.9 VDR TP53 PTGS2 MTHFR MIR21 IGF1
33 gallbladder disease 29.9 TP53 MIR17 KRAS HRAS CDH1
34 barrett esophagus 29.8 TP53 PTGS2 ODC1 MYC MGMT CTNNB1
35 inflammatory bowel disease 29.8 VDR TP53 PTGS2 MYC MTHFR MLH1
36 li-fraumeni syndrome 29.8 TP53 MYC MUTYH MSH2 MLH1 KRAS
37 endometrial cancer 29.6 TP53 MYC MUTYH MSH2 MLH1 KRAS
38 rectum cancer 29.6 VDR MUTYH MSH2 MLH1 MIR21 MIR17
39 colon adenocarcinoma 29.4 TP53 PTGS2 ODC1 MYC MLH1 MIR21
40 hepatitis b 29.4 TP53 MYC MIR21 MIR17
41 diabetes mellitus, noninsulin-dependent 29.3 VDR TP53 PTGS2 MTHFR MIR21 MIR17
42 skin carcinoma 29.3 VDR TP53 PTGS2 ODC1 MSH2 MIR21
43 gastric adenocarcinoma 29.1 TP53 PTGS2 ODC1 MYC MLH1 MGMT
44 colorectal cancer 28.8 VDR TP53 PTGS2 ODC1 MYC MUTYH
45 medulloblastoma 28.8 TP53 PTGS2 ODC1 MYC MSH2 MIR17
46 b-cell lymphoma 28.7 TP53 MYC MIR21 MIR17 MIR15A MGMT
47 ovarian cancer 28.4 TP53 PTGS2 MYC MSH2 MLH1 MIR21
48 esophageal cancer 28.4 TP53 PTGS2 MYC MTHFR MSH2 MLH1
49 gastrointestinal system disease 28.2 MIR21 MIR17 MIR15A APC
50 myeloma, multiple 28.1 TP53 MYC MIR21 MIR17 MIR15A KRAS

Graphical network of the top 20 diseases related to Colorectal Adenoma:



Diseases related to Colorectal Adenoma

Symptoms & Phenotypes for Colorectal Adenoma

GenomeRNAi Phenotypes related to Colorectal Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Salmonella enterica Typhimurium membrane closure GR00133-A-6 9.33 MSH2 MYC ODC1
2 Reduced mammosphere formation GR00396-S 9.17 CDH1 HRAS IGF1 KRAS MUTYH MYC
3 Decreased Salmonella-containing vacuole maturation GR00133-A-2 9.13 MSH2 MYC ODC1

MGI Mouse Phenotypes related to Colorectal Adenoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 APC CDH1 CTNNB1 GREM1 IGF1 KRAS
2 homeostasis/metabolism MP:0005376 10.44 APC CDH1 CTNNB1 GREM1 HRAS IGF1
3 mortality/aging MP:0010768 10.41 APC CDH1 CTNNB1 GREM1 HRAS IGF1
4 growth/size/body region MP:0005378 10.37 APC CDH1 CTNNB1 GREM1 HRAS IGF1
5 endocrine/exocrine gland MP:0005379 10.35 APC CDH1 CTNNB1 HRAS IGF1 KRAS
6 digestive/alimentary MP:0005381 10.32 APC CDH1 CTNNB1 HRAS KRAS MLH1
7 integument MP:0010771 10.32 APC CDH1 CTNNB1 HRAS IGF1 KRAS
8 cardiovascular system MP:0005385 10.3 APC CDH1 CTNNB1 HRAS IGF1 KRAS
9 immune system MP:0005387 10.26 APC CDH1 CTNNB1 IGF1 KRAS MLH1
10 neoplasm MP:0002006 10.25 APC CDH1 CTNNB1 HRAS IGF1 KRAS
11 nervous system MP:0003631 10.25 APC CTNNB1 GREM1 HRAS IGF1 KRAS
12 embryo MP:0005380 10.23 APC CDH1 CTNNB1 GREM1 KRAS MYC
13 limbs/digits/tail MP:0005371 10.15 APC CTNNB1 GREM1 IGF1 KRAS MTHFR
14 craniofacial MP:0005382 10.14 APC CTNNB1 HRAS KRAS MYC TP53
15 hearing/vestibular/ear MP:0005377 10.09 APC CTNNB1 IGF1 KRAS MYC TP53
16 muscle MP:0005369 10.06 APC CTNNB1 IGF1 KRAS MYC PTGS2
17 no phenotypic analysis MP:0003012 10.02 CDH1 CTNNB1 HRAS KRAS MGMT MTHFR
18 normal MP:0002873 10.02 APC CDH1 CTNNB1 HRAS IGF1 KRAS
19 reproductive system MP:0005389 9.93 APC CDH1 CTNNB1 GREM1 IGF1 KRAS
20 renal/urinary system MP:0005367 9.91 APC CTNNB1 GREM1 HRAS IGF1 KRAS
21 respiratory system MP:0005388 9.61 CTNNB1 GREM1 HRAS IGF1 KRAS MGMT
22 skeleton MP:0005390 9.36 APC CTNNB1 GREM1 HRAS IGF1 KRAS

Drugs & Therapeutics for Colorectal Adenoma

Drugs for Colorectal Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anesthetics Phase 4
2
Calcium carbonate Approved, Investigational Phase 3 471-34-1
3
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
4
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
5
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
6
Zinc Approved, Investigational Phase 3 7440-66-6 32051
7
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
8
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
9
Calcitriol Approved, Nutraceutical Phase 3 32222-06-3 134070 5280453
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
11
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
13 Tocotrienol Investigational Phase 3 6829-55-6
14 Omega 3 Fatty Acid Phase 2, Phase 3
15 Analgesics Phase 3
16 Cyclooxygenase Inhibitors Phase 3
17 Analgesics, Non-Narcotic Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 3
19 Anti-Inflammatory Agents Phase 3
20 Antirheumatic Agents Phase 3
21 Acetylsalicylic acid lysinate Phase 3
22 Micronutrients Phase 3
23 Trace Elements Phase 3
24 Vitamins Phase 3
25 Nutrients Phase 3
26 Calcium, Dietary Phase 3
27 Calciferol Phase 3
28 Hormones Phase 3
29 Cola Phase 3
30 Fibrinolytic Agents Phase 3
31 Platelet Aggregation Inhibitors Phase 3
32 Antipyretics Phase 3
33 Vasoconstrictor Agents Phase 3
34 Dihydroxycholecalciferols Phase 3
35 Antioxidants Phase 3
36 Tocopherols Phase 3
37 Tocotrienols Phase 3
38 Protective Agents Phase 3
39 Hypolipidemic Agents Phase 3
40 Anticholesteremic Agents Phase 3
41 Rosuvastatin Calcium Phase 3 147098-20-2
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
43 Lipid Regulating Agents Phase 3
44 Antimetabolites Phase 3
45 retinol Phase 3
46 Retinol palmitate Phase 3
47
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
48
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
49
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
50
Linaclotide Approved Phase 2 851199-59-2 65351

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
2 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
3 Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial Unknown status NCT02143505 Phase 2, Phase 3 Ca plus vit D
4 A Randomize Controlled Trial of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer Unknown status NCT02066688 Phase 2, Phase 3 folic acid;folic acid calcium vitamin D3;calcium
5 A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas Completed NCT02226185 Phase 2, Phase 3 Berberine hydrochloride;placebo
6 A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas Completed NCT00282386 Phase 3 MK0966; Rofecoxib / Duration of Treatment: 156 weeks;Placebo/ Duration of Treatment: 156 weeks
7 Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Completed NCT00141193 Phase 3 Celecoxib
8 S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT Completed NCT00706121 Phase 3 Vitamin E;Selenium;Vitamin E placebo;selenium placebo
9 Prevention of Sporadic Colorectal Adenomas With Celecoxib Completed NCT00005094 Phase 3 celecoxib
10 Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study Completed NCT00002527 Phase 3 aspirin
11 A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
12 Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Recruiting NCT02813824 Phase 3 Acetylsalicylic acid lysinate 300 mg;Placebo (for Aspirin 300);Acetylsalicylic acid lysinate 100 mg;Placebo 100 (for Aspirin 100)
13 A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer Recruiting NCT03281096 Phase 2, Phase 3 Berberine hydrochloride;Placebo
14 The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial Recruiting NCT03333265 Phase 2, Phase 3 100mg Berberine hydrochloride;300mg Berberine hydrochloride;Placebo Oral Tablet
15 Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial Recruiting NCT02607072 Phase 3 Acetylsalicylic acid (ASA)/aspirin 200 mg daily;Acetylsalicylic acid (ASA)/aspirin 100 mg daily;Placebo
16 A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas Terminated NCT00486512 Phase 3 aspirin, 1,25-dihydroxycholecalciferol, calcium;placebo
17 Statin Polyp Prevention Trial in Patients With Resected Colon Cancer Terminated NCT01011478 Phase 3 rosuvastatin
18 Evaluation of the Efficacy of a Combination of Micronutrients (Vitamin A, C, E, Selenium and Zinc) in Reducing the Incidence of Colorectal Metachronous Adenomas. A Double Blind, Phase III, Randomized, Placebo-controlled Trial Terminated NCT01437826 Phase 3 antioxidants;placebo
19 Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence Terminated NCT00224679 Phase 3 Aspirin
20 3389 Colorectal Adenoma: Chemoprevention With Folic Acid Completed NCT00018551 Phase 2 Folic Acid
21 Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas Completed NCT01894685 Phase 2 Mesalazine;Placebo
22 Randomized, Placebo-Controlled, Phase 2B Evaluation of Cyclooxygenase-2 Activity in Surgically Resected Primary Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
23 A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index Completed NCT01312467 Phase 2 metformin hydrochloride
24 Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE- Completed NCT01360320 Phase 2
25 Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma Completed NCT00773097 Phase 2
26 Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Completed NCT01187901 Phase 2 Erlotinib;Sulindac;Placebo A;Placebo B
27 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
28 Fatty Acid Desaturase Activity, Fish Oil and Colorectal Cancer Prevention Completed NCT01661764 Phase 2 Eicosapentanoic acid and docosahexanoic acid;Oleic Acid
29 Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer Recruiting NCT03796884 Phase 2 Linaclotide
30 Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention Recruiting NCT02965703 Phase 2 Aspirin
31 A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. The ASAMET Trial Recruiting NCT03047837 Phase 2 Aspirin (ASA) + Metformin (MET);ASA;MET;Placebos
32 Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas Active, not recruiting NCT02134925 Phase 2
33 Panoramic Screening by Complete Colonoscopy in the Management of Colorectal Adenomas Not yet recruiting NCT03961893 Phase 2
34 PREPARE: PRevention Using EPA Against coloREctal Cancer Not yet recruiting NCT04172636 Phase 2 AMR101 (VASCEPA, icosapent ethyl)
35 Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer Terminated NCT01856322 Phase 2 Sulindac;Placebo
36 Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia Terminated NCT01606124 Phase 2 defined green tea catechin extract
37 Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Withdrawn NCT03185871 Phase 2 Celecoxib
38 A Prospective Investigation of the ColubrisMX Endoluminal Surgical (ELS) System Active, not recruiting NCT04192565 Phase 1
39 Detection of Colorectal Adenomas in Côte-d'Or: Impact of Organized Screening on Socio-geographic Disparities Unknown status NCT02859714
40 Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy: A Randomized Trial Unknown status NCT02865382
41 Clinical Study That Effect of Individualized Intervention of Single Colonoscopy on Colorectal Adenomas Detection Unknown status NCT02693886
42 UKCAP Trial: A Multi-Center Double Blind Randomised Controlled Trial Of Aspirin And/Or Folate Supplementation For the Prevention Of Recurrent Colorectal Adenomas Unknown status NCT00033319 acetylsalicylic acid
43 Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique Unknown status NCT02935049
44 Prevalence of Colorectal Adenoma in 30- to 49-year-old Asymptomatic Subjects With a First Relative History of Colorectal Cancer Unknown status NCT01428752
45 Endoscopic Full Thickness Resection in the Lower GI Tract With the "Full Thickness Resection Device"- A Prospective Multicenter Trial Unknown status NCT02362126
46 Intubation Techniques on Colonoscopy Quality: A Single Center Randomized Control Clinical Trial Unknown status NCT01919463
47 Comparison of Detection and Miss Rates of Colorectal Adenoma by Blue Laser Imaging (BLI) Versus Conventional White Light Colonoscopy. Unknown status NCT02982447
48 Efficacy of Segmental Re-examination and Retroflexion of Proximal Colon for Adenoma Miss Rate During Colonoscopy Unknown status NCT03355443
49 A Pilot Study to Assess the Role for Endocuff© Assisted Colonoscopy in the Detection of Colonic Cancer and Polyps Unknown status NCT01761097
50 Effect of Water Exchange Method on Adenoma Miss Rates in Patients Undergoing Selective Polypectomy: a Single-centered, Randomized Controlled Study Unknown status NCT02880748

Search NIH Clinical Center for Colorectal Adenoma

Genetic Tests for Colorectal Adenoma

Genetic tests related to Colorectal Adenoma:

# Genetic test Affiliating Genes
1 Colorectal Adenoma 29

Anatomical Context for Colorectal Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Colorectal Adenoma:

19
Colon, Rectum

MalaCards organs/tissues related to Colorectal Adenoma:

40
Colon, Testes, Breast, Liver, Bone, Lung, Skin

Publications for Colorectal Adenoma

Articles related to Colorectal Adenoma:

(show top 50) (show all 3766)
# Title Authors PMID Year
1
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression. 61
31411736 2020
2
Dose-response meta-analysis of coffee consumption and risk of colorectal adenoma. 61
31308476 2020
3
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. 61
31818523 2020
4
Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia. 61
31816287 2020
5
No Increased Risk of Colorectal Adenomas in Spouses of Patients with Colorectal Neoplasia. 61
30928453 2020
6
Nutritional prevention of colorectal cancer. 61
32019626 2020
7
Epigenetics of colorectal cancer: biomarker and therapeutic potential. 61
31900466 2020
8
Dietary nutrient patterns and the risk of colorectal cancer and colorectal adenomas: a case-control study. 61
32039932 2020
9
Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. 61
32032128 2020
10
A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. 61
31818851 2020
11
Cytotoxin-associated gene A increases carcinogenicity of helicobacter pylori in colorectal adenoma. 61
31971064 2020
12
Genome-wide analysis of DNA methylation identifies two CpG sites for the early screening of colorectal cancer. 61
31762318 2020
13
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. 61
31926918 2020
14
Doneness preferences, meat and meat-derived heterocyclic amines intake, and N-acetyltransferase 2 polymorphisms: association with colorectal adenoma in Japanese Brazilians. 61
30913095 2020
15
Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study. 61
31981518 2020
16
Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia. 61
31948419 2020
17
BMP-9 is a novel marker for colorectal tumorigenesis undergoing the normal mucosa-adenoma-adenocarcinoma sequence and is associated with colorectal cancer prognosis. 61
31897139 2020
18
Integrative systematic review meta-analysis and bioinformatics identifies MicroRNA-21 and its target genes as biomarkers for colorectal adenocarcinoma. 61
31756546 2020
19
SFRP1 promotor methylation analysis of FTA card touch-prep samples derived from colonic polyps. 61
32007530 2020
20
Colorectal polyp prevalence and aspirational detection targets determined using high definition colonoscopy and a high level detector in 2017. 61
31543411 2020
21
Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. 61
31926173 2020
22
Pathways of Colorectal Carcinogenesis. 61
31622622 2020
23
APC transcription studies and molecular diagnosis of familial adenomatous polyposis. 61
31383941 2020
24
The association between colorectal cancer and prior antibiotic prescriptions: case control study. 61
31929515 2020
25
Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions. 61
30997628 2019
26
Antibiotic exposure and the risk of colorectal adenoma and carcinoma: a systematic review and meta-analysis of observational studies. 61
31802593 2019
27
The short-term outcomes of laparoscopic-endoscopic cooperative surgery for colorectal tumors (LECS-CR) in cases involving endoscopically unresectable colorectal tumors. 61
31250113 2019
28
Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study. 61
31856598 2019
29
Low folate status, and MTHFR 677C > T and MTR 2756A > G polymorphisms associated with colorectal cancer risk in Thais: a case-control study. 61
31740010 2019
30
Statin Treatment, Early Pregnancy Loss, Ingrown Toenails, Blood Pressure, ADHD, Colorectal Adenomas. 61
31790185 2019
31
Identification of Lynch syndrome by microsatellite instability and mismatch repair deficiency testing on colorectal adenomas. 61
31857714 2019
32
Location of colorectal adenomas and serrated polyps in patients under age 50. 61
31735986 2019
33
Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria. 61
31805871 2019
34
Association of a New Germline Variant in the MUTYH DNA Glycosylase Gene with Colorectal Adenoma Transformation into Malignancy 61
31104418 2019
35
Impact of linked-color imaging on colorectal adenoma detection. 61
31302092 2019
36
A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. 61
31776231 2019
37
Additively protective effects of vitamin D and calcium against colorectal adenoma incidence, malignant transformation and progression: A systematic review and meta-analysis. 61
31784301 2019
38
Proteinase K Combining Two-Step Liquid-Liquid Extraction for Plasma Untargeted Liquid Chromatography-Mass Spectrometry-Based Metabolomics To Discover the Potential Mechanism of Colorectal Adenoma. 61
31613596 2019
39
Proteome analysis of formalin-fixed paraffin-embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas. 61
31729028 2019
40
Endocytoscopy for the differential diagnosis of colorectal low-grade adenoma: a novel possibility for the "resect and discard" strategy. 61
31785276 2019
41
Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression. 61
31784980 2019
42
Underwater cold snare polypectomy for colorectal adenomas. 61
31038769 2019
43
Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial. 61
31750855 2019
44
Genome-wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosine-phosphate-guanine methylation and histological subtypes. 61
31334584 2019
45
Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. 61
31695176 2019
46
KRAS mutation and abnormal expression of Cripto-1 as two potential candidate biomarkers for detection of colorectal cancer development. 61
31692030 2019
47
Healthy Eating Index-2010 and Mediterranean-Style Dietary Pattern Score and the risk of colorectal cancer and adenoma: a case-control study. 61
31687849 2019
48
Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. 61
31484660 2019
49
Outcomes at follow-up of negative colonoscopy in average risk population: systematic review and meta-analysis. 61
31722884 2019
50
Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition. 61
31694571 2019

Variations for Colorectal Adenoma

ClinVar genetic disease variations for Colorectal Adenoma:

6 (show all 13) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.2847G>T (p.Met949Ile)SNV Conflicting interpretations of pathogenicity 161206 rs147394539 5:112174138-112174138 5:112838441-112838441
2 APC NM_000038.6(APC):c.7778A>G (p.Asn2593Ser)SNV Conflicting interpretations of pathogenicity 161205 rs367676584 5:112179069-112179069 5:112843372-112843372
3 APC NM_000038.6(APC):c.3479C>A (p.Thr1160Lys)SNV Conflicting interpretations of pathogenicity 41503 rs201004111 5:112174770-112174770 5:112839073-112839073
4 APC NM_000038.6(APC):c.7717A>G (p.Ile2573Val)SNV Conflicting interpretations of pathogenicity 41536 rs145444830 5:112179008-112179008 5:112843311-112843311
5 APC NM_000038.6(APC):c.4360A>G (p.Lys1454Glu)SNV Conflicting interpretations of pathogenicity 127295 rs111866410 5:112175651-112175651 5:112839954-112839954
6 APC NM_000038.6(APC):c.4237A>G (p.Met1413Val)SNV Conflicting interpretations of pathogenicity 133510 rs141519952 5:112175528-112175528 5:112839831-112839831
7 APC NM_000038.6(APC):c.8266A>G (p.Ile2756Val)SNV Conflicting interpretations of pathogenicity 135724 rs146115809 5:112179557-112179557 5:112843860-112843860
8 APC NM_000038.6(APC):c.4732T>G (p.Cys1578Gly)SNV Conflicting interpretations of pathogenicity 140839 rs138367627 5:112176023-112176023 5:112840326-112840326
9 APC NM_000038.6(APC):c.8383G>A (p.Ala2795Thr)SNV Conflicting interpretations of pathogenicity 141047 rs369264968 5:112179674-112179674 5:112843977-112843977
10 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg)SNV Uncertain significance 141928 rs371085910 5:112111352-112111352 5:112775655-112775655
11 APC NM_000038.6(APC):c.4420G>A (p.Ala1474Thr)SNV Benign/Likely benign 133530 rs139387758 5:112175711-112175711 5:112840014-112840014
12 APC NM_000038.6(APC):c.6985A>G (p.Ile2329Val)SNV Benign/Likely benign 135716 rs146048493 5:112178276-112178276 5:112842579-112842579
13 APC NM_000038.6(APC):c.4336G>A (p.Ala1446Thr)SNV Benign/Likely benign 127294 rs146572883 5:112175627-112175627 5:112839930-112839930

Expression for Colorectal Adenoma

LifeMap Discovery
Genes differentially expressed in tissues of Colorectal Adenoma patients vs. healthy controls: 35 (show top 50) (show all 255)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GCG glucagon Colon - 9.14 0.000
2 GUCA2B guanylate cyclase activator 2B (uroguanylin) Colon - 8.78 0.000
3 MS4A12 membrane-spanning 4-domains, subfamily A, member 12 Colon - 8.78 0.000
4 AQP8 aquaporin 8 Colon - 8.30 0.000
5 CA1 carbonic anhydrase I Colon - 8.11 0.000
6 CLCA4 chloride channel accessory 4 Colon - 7.63 0.000
7 CA4 carbonic anhydrase IV Colon - 7.51 0.000
8 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Colon + 7.34 0.000
9 CLDN8 claudin 8 Colon - 7.18 0.000
10 CDH3 cadherin 3, type 1, P-cadherin (placental) Colon + 6.97 0.000
11 GUCA2A guanylate cyclase activator 2A (guanylin) Colon - 6.92 0.000
12 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 Colon - 6.85 0.001
13 PRAC1 prostate cancer susceptibility candidate 1 Colon - 6.72 0.040
14 CEMIP cell migration inducing protein, hyaluronan binding Colon + 6.69 0.000
15 INSL5 insulin-like 5 Colon - 6.67 0.000
16 PYY peptide YY Colon - 6.57 0.000
17 SCNN1B sodium channel, non voltage gated 1 beta subunit Colon - 6.53 0.000
18 CHGA chromogranin A Colon - 6.30 0.000
19 SST somatostatin Colon - 5.99 0.000
20 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) Colon - 5.77 0.002
21 SLC51B solute carrier family 51, beta subunit Colon - 5.54 0.001
22 CD177 CD177 molecule Colon - 5.52 0.003
23 GCNT2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) Colon - 5.48 0.000
24 SLC25A34 solute carrier family 25, member 34 Colon - 5.43 0.000
25 SLC26A3 solute carrier family 26 (anion exchanger), member 3 Colon - 5.39 0.002
26 CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) Colon - 5.35 0.000
27 ZG16 zymogen granule protein 16 Colon - 5.34 0.000
28 MSX2 msh homeobox 2 Colon + 5.31 0.000
29 FABP6 fatty acid binding protein 6, ileal Colon + 5.29 0.000
30 EPHX4 epoxide hydrolase 4 Colon + 5.24 0.000
31 DUSP27 dual specificity phosphatase 27 (putative) Colon + 5.23 0.000
32 TACSTD2 tumor-associated calcium signal transducer 2 Colon + 5.10 0.000
33 GABRP gamma-aminobutyric acid (GABA) A receptor, pi Colon + 5.08 0.003
34 BEST4 bestrophin 4 Colon - 5.08 0.001
35 S100A2 S100 calcium binding protein A2 Colon + 5.05 0.000
36 DPEP1 dipeptidase 1 (renal) Colon + 5.04 0.010
37 MUC12 mucin 12, cell surface associated Colon - 4.98 0.020
38 SPINK5 serine peptidase inhibitor, Kazal type 5 Colon - 4.96 0.001
39 PCSK1 proprotein convertase subtilisin/kexin type 1 Colon + 4.92 0.008
40 SLC30A10 solute carrier family 30, member 10 Colon - 4.89 0.003
41 TMEM72 transmembrane protein 72 Colon - 4.88 0.000
42 KLK10 kallikrein-related peptidase 10 Colon + 4.85 0.020
43 CDH19 cadherin 19, type 2 Colon - 4.83 0.001
44 CDKN2B-AS1 CDKN2B antisense RNA 1 Colon - 4.75 0.004
45 MT1M metallothionein 1M Colon - 4.75 0.027
46 SLC6A19 solute carrier family 6 (neutral amino acid transporter), member 19 Colon - 4.71 0.007
47 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.70 0.000
48 ANO5 anoctamin 5 Colon - 4.68 0.000
49 FOXQ1 forkhead box Q1 Colon + 4.62 0.000
50 CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7 Colon - 4.60 0.001
Search GEO for disease gene expression data for Colorectal Adenoma.

Pathways for Colorectal Adenoma

Pathways related to Colorectal Adenoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 TP53 PTGS2 MYC KRAS IGF1 HRAS
2
Show member pathways
12.99 TP53 KRAS IGF1 HRAS CTNNB1 CDH1
3
Show member pathways
12.97 TP53 PTGS2 MYC KRAS IGF1 HRAS
4
Show member pathways
12.94 TP53 PTGS2 MSH2 MLH1 KRAS HRAS
5
Show member pathways
12.94 TP53 PTGS2 MYC KRAS HRAS CTNNB1
6
Show member pathways
12.83 TP53 MYC KRAS IGF1 HRAS
7 12.78 TP53 MYC KRAS IGF1 HRAS
8
Show member pathways
12.77 TP53 MYC MSH2 MLH1 KRAS IGF1
9
Show member pathways
12.75 KRAS IGF1 HRAS CTNNB1 CDH1
10
Show member pathways
12.72 TP53 MYC MLH1 KRAS IGF1 HRAS
11
Show member pathways
12.71 TP53 MYC MSH2 MGMT IGF1
12
Show member pathways
12.7 TP53 PTGS2 KRAS HRAS CTNNB1 CDH1
13
Show member pathways
12.69 TP53 KRAS IGF1 HRAS CDH1
14
Show member pathways
12.64 TP53 MYC KRAS IGF1 HRAS
15 12.62 TP53 PTGS2 MYC MSH2 MLH1 KRAS
16
Show member pathways
12.61 TP53 MYC MSH2 KRAS HRAS CTNNB1
17
Show member pathways
12.52 TP53 MYC KRAS HRAS CTNNB1 CDH1
18 12.51 TP53 MUTYH MSH2 MLH1 MGMT
19
Show member pathways
12.5 TP53 KRAS IGF1 HRAS APC
20 12.47 TP53 PTGS2 MYC CTNNB1 CDH1 APC
21
Show member pathways
12.41 PTGS2 KRAS HRAS CTNNB1
22
Show member pathways
12.41 TP53 MYC IGF1 HRAS
23
Show member pathways
12.4 KRAS IGF1 HRAS CTNNB1 CDH1 APC
24 12.4 TP53 PTGS2 MYC MIR21 MIR17 MIR15A
25
Show member pathways
12.39 TP53 MYC MIR17 IGF1
26 12.38 TP53 MYC CDH1 APC
27 12.35 TP53 MYC KRAS HRAS
28 12.29 TP53 MYC MIR21 KRAS IGF1 HRAS
29
Show member pathways
12.24 TP53 MYC CTNNB1 APC
30 12.18 TP53 MYC KRAS HRAS
31 12.15 MYC CTNNB1 CDH1 APC
32
Show member pathways
12.14 TP53 MYC KRAS HRAS
33
Show member pathways
12.13 TP53 KRAS IGF1 HRAS
34 12.1 VDR TP53 MSH2 MLH1 APC
35 12.1 MYC KRAS IGF1 HRAS CTNNB1 APC
36 12.1 TP53 ODC1 MYC MSH2 KRAS CTNNB1
37 12.06 KRAS HRAS CTNNB1 CDH1 APC
38 12.03 TP53 MYC KRAS HRAS CTNNB1
39 11.99 TP53 MYC KRAS HRAS CTNNB1 APC
40 11.82 MYC CTNNB1 CDH1 APC
41 11.81 TP53 ODC1 MYC
42 11.76 TP53 MSH2 MLH1
43 11.76 TP53 MYC KRAS HRAS CDH1
44 11.75 TP53 MYC KRAS HRAS
45 11.72 MYC CTNNB1 APC
46 11.7 TP53 MYC HRAS
47 11.69 TP53 KRAS HRAS
48 11.65 KRAS IGF1 HRAS
49 11.6 TP53 MYC MGMT KRAS IGF1 HRAS
50 11.59 MYC CTNNB1 APC

GO Terms for Colorectal Adenoma

Cellular components related to Colorectal Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 9.16 CTNNB1 CDH1
2 lateral plasma membrane GO:0016328 9.13 CTNNB1 CDH1 APC
3 catenin complex GO:0016342 8.8 CTNNB1 CDH1 APC

Biological processes related to Colorectal Adenoma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 VDR TP53 MYC IGF1 HRAS GREM1
2 positive regulation of transcription, DNA-templated GO:0045893 10.03 TP53 MYC IGF1 GREM1 CTNNB1 CDH1
3 cellular response to DNA damage stimulus GO:0006974 10 TP53 MYC MUTYH MSH2 MLH1 MGMT
4 positive regulation of cell migration GO:0030335 9.97 MIR21 IGF1 HRAS APC
5 regulation of gene expression GO:0010468 9.97 MYC IGF1 CTNNB1 CDH1
6 positive regulation of apoptotic process GO:0043065 9.97 TP53 PTGS2 MIR21 MIR15A CTNNB1 APC
7 negative regulation of apoptotic process GO:0043066 9.92 TP53 PTGS2 MYC MIR21 MGMT IGF1
8 negative regulation of gene expression GO:0010629 9.88 TP53 MIR21 MIR17 IGF1 HRAS CTNNB1
9 cellular response to hypoxia GO:0071456 9.85 TP53 PTGS2 MYC MIR17
10 cell cycle arrest GO:0007050 9.83 TP53 MYC MSH2 HRAS APC
11 positive regulation of epithelial cell proliferation GO:0050679 9.81 MYC IGF1 HRAS
12 positive regulation of osteoblast differentiation GO:0045669 9.8 MIR21 IGF1 CTNNB1
13 response to drug GO:0042493 9.8 TP53 PTGS2 MYC MTHFR MGMT CTNNB1
14 positive regulation of fibroblast proliferation GO:0048146 9.79 MYC MIR17 IGF1
15 cellular response to UV GO:0034644 9.78 TP53 PTGS2 MYC
16 Ras protein signal transduction GO:0007265 9.78 TP53 KRAS IGF1 HRAS
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.77 MIR21 MIR17 IGF1
18 positive regulation of gene expression GO:0010628 9.76 VDR TP53 MYC MIR21 KRAS IGF1
19 positive regulation of telomerase activity GO:0051973 9.71 MYC GREM1 CTNNB1
20 mismatch repair GO:0006298 9.7 MUTYH MSH2 MLH1
21 response to UV-B GO:0010224 9.66 TP53 MSH2
22 positive regulation of isotype switching to IgG isotypes GO:0048304 9.66 MSH2 MLH1
23 positive regulation of metalloendopeptidase activity GO:1904685 9.65 MIR21 MIR17
24 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.65 MIR21 IGF1
25 endothelial tube morphogenesis GO:0061154 9.65 MIR21 CTNNB1
26 response to folic acid GO:0051593 9.64 MTHFR MGMT
27 entry of bacterium into host cell GO:0035635 9.64 CTNNB1 CDH1
28 response to isolation stress GO:0035900 9.62 KRAS HRAS
29 signal transduction by p53 class mediator GO:0072331 9.59 TP53 GREM1
30 cellular response to indole-3-methanol GO:0071681 9.58 CTNNB1 CDH1
31 positive regulation of isotype switching to IgA isotypes GO:0048298 9.58 MSH2 MLH1
32 somatic recombination of immunoglobulin gene segments GO:0016447 9.57 MSH2 MLH1
33 negative regulation of cell proliferation GO:0008285 9.56 VDR TP53 PTGS2 MIR21 MIR15A HRAS
34 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR21 MIR17 IGF1
35 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.51 MSH2 MLH1
36 positive regulation of cell proliferation GO:0008284 9.28 PTGS2 ODC1 MYC MIR21 KRAS IGF1

Molecular functions related to Colorectal Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.88 TP53 PTGS2 ODC1 MSH2 GREM1 CDH1
2 protein C-terminus binding GO:0008022 9.67 TP53 MSH2 HRAS CTNNB1
3 enzyme binding GO:0019899 9.35 TP53 PTGS2 MSH2 MLH1 CTNNB1
4 MutSalpha complex binding GO:0032407 9.32 MUTYH MLH1
5 MutLalpha complex binding GO:0032405 9.26 MUTYH MSH2
6 oxidized purine DNA binding GO:0032357 9.16 MUTYH MSH2
7 guanine/thymine mispair binding GO:0032137 8.62 MSH2 MLH1

Sources for Colorectal Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....